Please assess the completion status of the following clinical trial:

Trial Title: Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Give written informed consent~* Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal. Males must be surgically sterile, abstinent, or if engaged in sexual relations of child-bearing potential, must use contraception~* Undergoing elective, primary unilateral total knee arthroplasty~Exclusion Criteria:~* Body weight \<50 kg~* Patients at increased risk of bleeding. History of intracranial or intraocular bleeding. History of gastrointestinal and/or endoscopically verified ulcer disease within the past year.~* History of excessive intra- or direct post operative bleeding or a traumatic spinal or epidural anesthesia~* Brain, spinal, or ophthalmologic surgery within the past 3 months~* History of clinically significant liver disease in the past year~* Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values~  * aPTT or PT or INR \>ULN~ * Factor IX activity \<LLN~ * Factor VIII activity, vWF antigen or Ristocetin cofactor activity \<0.5 U/mL~ * FXI activity \<0.3 U/mL~ * Urine protein or blood persistently positive by dipstick. In the event of positive test results, eligibility may be confirmed with urine microscopy or 24 hour urine protein measurement as applicable~ * ALT or AST \>1.5 x ULN~ * Total bilirubin \>ULN~ * Platelet count \<150,000 (or history of thrombocytopenia)~* Hypersensitivity to enoxaparin~* Anticipated concomitant use of anticoagulants/antiplatelet agents or the NSAID nimesulide that may affect study outcome or any other drug influencing coagulation (except low dose aspirin and short acting NSAIDs with a half-life \<20 hours) at least 7 days before surgery or during treatment with ISIS Rx.~* Anticipated use of indwelling intrathecal or epidural catheters~* Anemia at Screening~* Have any other conditions which could interfere with the patient participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-FXIRx Dose 2 (Type: EXPERIMENTAL): Group B: ISIS-FXIRx Dose #2
- ISIS-FXIRx Dose 3 (Type: EXPERIMENTAL): Group C: ISIS-FXIRx Dose #3
- Enoxaparin (Type: ACTIVE_COMPARATOR): Enoxaparin (40mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).